Active drug shortages in the U.S. rose for the second consecutive quarter in 2026, reaching 223 in the first quarter, according to the American Society of Health-System Pharmacists — and the FDA’s database continues to reflect new discontinuations weekly. The database is updated daily to reflect manufacturing recoveries, regulatory actions and how shortages are classified — not solely day-to-day availability at the hospital level.
Here are five recent drug shortages, according to the FDA database:
- Caspofungin acetate injection: Sandoz discontinued the 5-milligram/milliliter and 7-milligram/milliliter vial presentations (manufactured by Jiangsu Hengrui Pharmaceuticals) on June 30. Fresenius Kabi discontinued its own 7-milligram/milliliter presentation in January.
- Daptomycin injection: Jiangsu Hengrui Pharmaceuticals discontinued two 500-milligram/10-milliliter presentations on June 30, one of them marketed by Hikma Pharmaceuticals.
- Gadobutrol injection: Fresenius Kabi discontinued four single-dose vial presentations of the 604.72-milligram/milliliter formulation on June 30. The company’s two Imaging Bulk Package strengths remain in supply.
- Gadoterate meglumine injection: Fresenius Kabi discontinued four presentations of the 376.9-milligram/milliliter formulation, according to the FDA database.
- Oxaliplatin injection: Sagent Pharmaceuticals discontinued two 5-milligram/milliliter presentations on June 29.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.